Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
2014
53
LTM Revenue $9.5M
LTM EBITDA n/a
$58.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cue Biopharma has a last 12-month revenue of $9.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cue Biopharma achieved revenue of $5.5M and an EBITDA of -$46.1M.
Cue Biopharma expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Cue Biopharma valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $1.2M | $5.5M | $9.4M | $9.5M | XXX |
Gross Profit | n/a | n/a | n/a | XXX | XXX |
Gross Margin | NaN% | NaN% | NaN% | XXX | XXX |
EBITDA | -$50.5M | -$46.1M | n/a | n/a | XXX |
EBITDA Margin | -4055% | -839% | NaN% | 0% | XXX |
Net Profit | -$44.2M | -$53.0M | -$50.7M | XXX | XXX |
Net Margin | -3546% | -966% | -539% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 10, 2025, Cue Biopharma's stock price is $1.
Cue Biopharma has current market cap of $81.1M, and EV of $58.2M.
See Cue Biopharma trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$58.2M | $81.1M | XXX | XXX | XXX | XXX | $-0.71 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 10, 2025, Cue Biopharma has market cap of $81.1M and EV of $58.2M.
Cue Biopharma's trades at 6.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cue Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cue Biopharma and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $58.2M | XXX | XXX | XXX |
EV/Revenue | 6.2x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | -2.0x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCue Biopharma's NTM/LTM revenue growth is 20%
Cue Biopharma's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Cue Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cue Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cue Biopharma and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 71% | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | 304% | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 743% | XXX | XXX | XXX | XXX |
Opex to Revenue | 1047% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cue Biopharma acquired XXX companies to date.
Last acquisition by Cue Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Cue Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Cue Biopharma founded? | Cue Biopharma was founded in 2014. |
Where is Cue Biopharma headquartered? | Cue Biopharma is headquartered in United States of America. |
How many employees does Cue Biopharma have? | As of today, Cue Biopharma has 53 employees. |
Who is the CEO of Cue Biopharma? | Cue Biopharma's CEO is Mr. Daniel R. Passeri. |
Is Cue Biopharma publicy listed? | Yes, Cue Biopharma is a public company listed on NAS. |
What is the stock symbol of Cue Biopharma? | Cue Biopharma trades under CUE ticker. |
When did Cue Biopharma go public? | Cue Biopharma went public in 2018. |
Who are competitors of Cue Biopharma? | Similar companies to Cue Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Cue Biopharma? | Cue Biopharma's current market cap is $81.1M |
What is the current revenue of Cue Biopharma? | Cue Biopharma's last 12-month revenue is $9.5M. |
What is the current EV/Revenue multiple of Cue Biopharma? | Current revenue multiple of Cue Biopharma is 6.1x. |
What is the current revenue growth of Cue Biopharma? | Cue Biopharma revenue growth between 2023 and 2024 was 71%. |
Is Cue Biopharma profitable? | Yes, Cue Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.